|
1
|
Al-Abed Y and VanPatten S: MIF as a
disease target: ISO-1 as a proof-of-concept therapeutic. Future Med
Chem. 3:45–63. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bach JP, Deuster O, Balzer-Geldsetzer M,
Meyer B, Dodel R and Bacher M: The role of macrophage inhibitory
factor in tumorigenesis and central nervous system tumors. Cancer.
115:2031–2040. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Girard E, Strathdee C, Trueblood E and
Queva C: Macrophage migration inhibitory factor produced by the
tumour stroma but not by tumour cells regulates angiogenesis in the
B16 F10 melanoma model. Br J Cancer. 107:1498–1505. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Choi S, Kim HR, Leng L, Kang I, Jorgensen
WL, Cho CS, Bucala R and Kim WU: Role of macrophage migration
inhibitory factor in the regulatory T cell response of
tumor-bearing mice. J Immunol. 189:3905–3913. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yaddanapudi K, Putty K, Rendon BE, Lamont
GJ, Faughn JD, Satoskar A, Lasnik A, Eaton JW and Mitchell RA:
Control of tumor-associated macrophage alternative activation by
macrophage migration inhibitory factor. J Immunol. 190:2984–2993.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Krockenberger M, Kranke P, Hausler S,
Engel JB, Horn E, Nurnberger K, Wischhusen J, Dietl J and Honig A:
Macrophage migration-inhibitory factor levels in serum of patients
with ovarian cancer correlates with poor prognosis. Anticancer Res.
32:5233–5238. 2012.PubMed/NCBI
|
|
7
|
Kindt N, Lechien J, Decaestecker C,
Rodriguez A, Chantrain G, Remmelink M, Laurent G, Gabius HJ and
Saussez S: Expression of macrophage migration-inhibitory factor is
correlated with progression in oral cavity carcinomas. Anticancer
Res. 32:4499–4505. 2012.PubMed/NCBI
|
|
8
|
Wang XB, Tian XY, Li Y, Li B and Li Z:
Elevated expression of macrophage migration inhibitory factor
correlates with tumor recurrence and poor prognosis of patients
with gliomas. J Neurooncol. 106:43–51. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Meyer-Siegler KL, Iczkowski KA, Leng L,
Bucala R and Vera PL: Inhibition of macrophage migration inhibitory
factor or its receptor (CD74) attenuates growth and invasion of DU
145 prostate cancer cells. J Immunol. 177:8730–8739. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rendon BE, Roger T, Teneng I, Zhao M,
Al-Abed Y, Calandra T and Mitchell RA: Regulation of human lung
adenocarcinoma cell migration and invasion by macrophage migration
inhibitory factor. J Biol Chem. 282:29910–29918. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lubetsky JB, Dios A, Han J, Aljabari B,
Ruzsicska B, Mitchell R, Lolis E and Al-Abed Y: The tautomerase
active site of macrophage migration inhibitory factor is a
potential target for discovery of novel anti-inflammatory agents. J
Biol Chem. 277:24976–24982. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Al-Abed Y, Dabideen D, Aljabari B, Valster
A, Messmer D, Ochani M, Tanovic M, Ochani K, Bacher M, Nicoletti F,
Metz C, Pavlov VA, Miller EJ and Tracey KJ: ISO-1 binding to the
tautomerase active site of MIF inhibits its pro-inflammatory
activity and increases survival in severe sepsis. J Biol Chem.
280:36541–36544. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Winner M, Meier J, Zierow S, Rendon BE,
Crichlow GV, Riggs R, Bucala R, Leng L, Smith N, Lolis E, Trent JO
and Mitchell RA: A novel, macrophage migration inhibitory factor
suicide substrate inhibits motility and growth of lung cancer
cells. Cancer Res. 68:7253–7257. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schrader J, Deuster O, Rinn B, Schulz M,
Kautz A, Dodel R, Meyer B, Al-Abed Y, Balakrishnan K, Reese JP and
Bacher M: Restoration of contact inhibition in human glioblastoma
cell lines after MIF knockdown. BMC Cancer. 9:4642009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Piette C, Deprez M, Roger T, Noel A,
Foidart JM and Munaut C: The dexamethasone-induced inhibition of
proliferation, migration, and invasion in glioma cell lines is
antagonized by macrophage migration inhibitory factor (MIF) and can
be enhanced by specific MIF inhibitors. J Biol Chem.
284:32483–32492. 2009. View Article : Google Scholar
|
|
16
|
He XX, Chen K, Yang J, Li XY, Gan HY, Liu
CY, Coleman TR and Al-Abed Y: Macrophage migration inhibitory
factor promotes colorectal cancer. Mol Med. 15:1–10.
2009.PubMed/NCBI
|
|
17
|
Barnick JWFK, Van Der Baan JL and
Bickelhaupt F: Convenient direct method for the preparation of
keto-acids. Synthesis. 79:787–788. 1979. View Article : Google Scholar
|
|
18
|
Rathkea MW and Nowaka MA: Synthesis of
beta-keto acids and methyl ketones using bis(trimethylsilyl)
malonate and triethylamine in the presence of lithium or magnesium
Halides. Synthesis Communications. 15:1039–1049. 1985. View Article : Google Scholar
|
|
19
|
Sun HW, Swope M, Cinquina C, Bedarkar S,
Bernhagen J, Bucala R and Lolis E: The subunit structure of human
macrophage migration inhibitory factor: evidence for a trimer.
Protein Eng. 9:631–635. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Crichlow GV, Cheng KF, Dabideen D, Ochani
M, Aljabari B, Pavlov VA, Miller EJ, Lolis E and Al-Abed Y:
Alternative chemical modifications reverse the binding orientation
of a pharmacophore scaffold in the active site of macrophage
migration inhibitory factor. J Biol Chem. 282:23089–23095. 2007.
View Article : Google Scholar
|
|
21
|
Brunger AT, Adams PD, Clore GM, DeLano WL,
Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu
NS, Read RJ, Rice LM, Simonson T and Warren GL: Crystallography
& NMR system: A new software suite for macromolecular structure
determination. Acta Crystallogr D Biol Crystallogr. 54:905–921.
1998.
|
|
22
|
Argyropoulou A, Samara P, Tsitsilonis O
and Skaltsa H: Polar constituents of Marrubium thessalum
Boiss. & Heldr (Lamiaceae) and their cytotoxic/cytostatic
activity. Phytother Res. 26:1800–1806. 2012.
|
|
23
|
Baxevanis CN, Voutsas IF, Tsitsilonis OE,
Gritzapis AD, Sotiriadou R and Papamichail M: Tumor-specific
CD4+ T lymphocytes from cancer patients are required for
optimal induction of cytotoxic T cells against the autologous
tumor. J Immunol. 164:3902–3912. 2000.PubMed/NCBI
|
|
24
|
Skopeliti M, Voutsas IF, Klimentzou P,
Tsiatas ML, Beck A, Bamias A, Moraki M, Livaniou E, Neagu M,
Voelter W and Tsitsilonis OE: The immunologically active site of
prothymosin alpha is located at the carboxy-terminus of the
polypeptide. Evaluation of its in vitro effects in cancer patients.
Cancer Immunol Immunother. 55:1247–1257. 2006. View Article : Google Scholar
|
|
25
|
Nair SK, Boczkowski D, Snyder D and Gilboa
E: Antigen-presenting cells pulsed with unfractionated
tumor-derived peptides are potent tumor vaccines. Eur J Immunol.
27:589–597. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ioannou K, Kavrochorianou N, Bega C,
Thyphronitis G, Haralambous S and Tsitsilonis O: The C-Terminal
decapeptide of prothymosin α induces a TH1-Type immune response in
vitro and retards tumor growth in vivo. In: 8th Joint Conference of
the International Cytokine Society and the International Society
for Interferon and Cytokine Research Elsevier; Chicago, IL. pp.
17–20. 2010
|
|
27
|
Shimizu T, Abe R, Nakamura H, Ohkawara A,
Suzuki M and Nishihira J: High expression of macrophage migration
inhibitory factor in human melanoma cells and its role in tumor
cell growth and angiogenesis. Biochem Biophys Res Commun.
264:751–758. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dessein AF, Stechly L, Jonckheere N,
Dumont P, Monte D, Leteurtre E, Truant S, Pruvot FR, Figeac M,
Hebbar M, Lecellier CH, Lesuffleur T, Dessein R, Grard G, Dejonghe
MJ, de Launoit Y, Furuichi Y, Prevost G, Porchet N, Gespach C and
Huet G: Autocrine induction of invasive and metastatic phenotypes
by the MIF-CXCR4 axis in drug-resistant human colon cancer cells.
Cancer Res. 70:4644–4654. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hudson JD, Shoaibi MA, Maestro R, Carnero
A, Hannon GJ and Beach DH: A proinflammatory cytokine inhibits p53
tumor suppressor activity. J Exp Med. 190:1375–1382. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun B, Nishihira J, Suzuki M, Fukushima N,
Ishibashi T, Kondo M, Sato Y and Todo S: Induction of macrophage
migration inhibitory factor by lysophosphatidic acid: relevance to
tumor growth and angiogenesis. Int J Mol Med. 12:633–641.
2003.PubMed/NCBI
|
|
31
|
Sun B, Nishihira J, Yoshiki T, Kondo M,
Sato Y, Sasaki F and Todo S: Macrophage migration inhibitory factor
promotes tumor invasion and metastasis via the Rho-dependent
pathway. Clin Cancer Res. 11:1050–1058. 2005.PubMed/NCBI
|
|
32
|
Apte RS, Sinha D, Mayhew E, Wistow GJ and
Niederkorn JY: Cutting edge: role of macrophage migration
inhibitory factor in inhibiting NK cell activity and preserving
immune privilege. J Immunol. 160:5693–5696. 1998.PubMed/NCBI
|
|
33
|
Yan X, Orentas RJ and Johnson BD:
Tumor-derived macrophage migration inhibitory factor (MIF) inhibits
T lymphocyte activation. Cytokine. 33:188–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Krockenberger M, Dombrowski Y, Weidler C,
Ossadnik M, Honig A, Hausler S, Voigt H, Becker JC, Leng L, Steinle
A, Weller M, Bucala R, Dietl J and Wischhusen J: Macrophage
migration inhibitory factor contributes to the immune escape of
ovarian cancer by down-regulating NKG2D. J Immunol. 180:7338–7348.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu L, Li Y, Sun H, Zhen X, Qiao C, Tian S
and Hou T: Current developments of macrophage migration inhibitory
factor (MIF) inhibitors. Drug Discov Today. 18:592–600. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Binsky I, Lantner F, Grabovsky V, Harpaz
N, Shvidel L, Berrebi A, Goldenberg DM, Leng L, Bucala R, Alon R,
Haran M and Shachar I: TAp63 regulates VLA-4 expression and chronic
lymphocytic leukemia cell migration to the bone marrow in a
CD74-dependent manner. J Immunol. 184:4761–4769. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ioannou K, Samara P, Livaniou E,
Derhovanessian E and Tsitsilonis OE: Prothymosin alpha: a
ubiquitous polypeptide with potential use in cancer diagnosis and
therapy. Cancer Immunol Immunother. 61:599–614. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
West PW, Parker LC, Ward JR and Sabroe I:
Differential and cell-type specific regulation of responses to
Toll-like receptor agonists by ISO-1. Immunology. 125:101–110.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chuang CC, Chuang YC, Chang WT, Chen CC,
Hor LI, Huang AM, Choi PC, Wang CY, Tseng PC and Lin CF: Macrophage
migration inhibitory factor regulates interleukin-6 production by
facilitating nuclear factor-kappa B activation during Vibrio
vulnificus infection. BMC Immunol. 11:502010. View Article : Google Scholar
|
|
40
|
Ogawa H, Nishihira J, Sato Y, Kondo M,
Takahashi N, Oshima T and Todo S: An antibody for macrophage
migration inhibitory factor suppresses tumour growth and inhibits
tumour-associated angiogenesis. Cytokine. 12:309–314. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Takahashi K, Koga K, Linge HM, Zhang Y,
Lin X, Metz CN, Al-Abed Y, Ojamaa K and Miller EJ: Macrophage CD74
contributes to MIF-induced pulmonary inflammation. Respir Res.
10:332009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Imai K and Takaoka A: Comparing antibody
and small-molecule therapies for cancer. Nat Rev Cancer. 6:714–727.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Engh RA and Huber R: Accurate bond and
angle parameters for X-ray protein structure refinement. Acta
Cryst. 47:392–400. 1991. View Article : Google Scholar
|
|
44
|
Cho Y, Crichlow GV, Vermeire JJ, Leng L,
Du X, Hodsdon ME, Bucala R, Cappello M, Gross M, Gaeta F, Johnson K
and Lolis EJ: Allosteric inhibition of macrophage migration
inhibitory factor revealed by ibudilast. Proc Natl Acad Sci USA.
107:11313–11318. 2010. View Article : Google Scholar : PubMed/NCBI
|
